Immutep Limited

When our Chief Scientific Officer, Dr. Frédéric Triebel, first discovered Lymphocyte Activation Gene-3 (LAG-3), he realized there was a novel pathway that could lead to valuable therapeutics for patients by harnessing the power of their own immune systems. This view centered on his findings around the interaction of LAG-3 and one of the central components of how our bodies respond to cancer, autoimmune diseases, and infection – the major histocompatibility complex class II (MHC II) – found on antigen-presenting cells.

Since those discoveries, Immutep has been a pioneer in developing therapeutics that are distinctly designed around the interplay of LAG-3 and MHC II to either stimulate or suppress the immune system to fight cancer or eradicate autoimmune diseases. Today, we have a diversified portfolio of cutting-edge immuno-oncology and targeted LAG-3 immunotherapy including three clinical stage candidates, one pre-clinical candidate, and one candidate that is early-stage.